BRPI0514115A - combination therapy employing transferrin fusion proteins comprising glp-1 - Google Patents
combination therapy employing transferrin fusion proteins comprising glp-1Info
- Publication number
- BRPI0514115A BRPI0514115A BRPI0514115-0A BRPI0514115A BRPI0514115A BR PI0514115 A BRPI0514115 A BR PI0514115A BR PI0514115 A BRPI0514115 A BR PI0514115A BR PI0514115 A BRPI0514115 A BR PI0514115A
- Authority
- BR
- Brazil
- Prior art keywords
- combination therapy
- transferrin fusion
- glp
- fusion proteins
- therapy employing
- Prior art date
Links
- 102000004338 Transferrin Human genes 0.000 title abstract 4
- 108090000901 Transferrin Proteins 0.000 title abstract 4
- 239000012581 transferrin Substances 0.000 title abstract 4
- 238000002648 combination therapy Methods 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 102000003729 Neprilysin Human genes 0.000 abstract 2
- 108090000028 Neprilysin Proteins 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
Abstract
TERAPIA DE COMBINAçãO EMPREGANDO-SE PROTEìNAS DE FUSãO DE TRANSFERRINA COMPREENDENDO GLP-1. A presente invenção fornece terapia de combinação compreendendo proteína de fusão de transferrina e inibidores de DPP-IV e inibidores de endopeptidase neutros (NEP). A proteína de fusão de transferrina compreende peptídeos ou polipeptídeos terapêuticos úteis no tratamento de doenças, tais como diabetes.COMBINATION THERAPY USING TRANSFERRIN FUSION PROTEMS UNDERSTANDING GLP-1. The present invention provides combination therapy comprising transferrin fusion protein and DPP-IV inhibitors and neutral endopeptidase (NEP) inhibitors. Transferrin fusion protein comprises therapeutic peptides or polypeptides useful in treating diseases such as diabetes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59803104P | 2004-08-03 | 2004-08-03 | |
| PCT/US2005/027800 WO2006017688A2 (en) | 2004-08-03 | 2005-08-03 | Combination therapy using transferrin fusion proteins comprising glp-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0514115A true BRPI0514115A (en) | 2008-05-27 |
Family
ID=35839920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0514115-0A BRPI0514115A (en) | 2004-08-03 | 2005-08-03 | combination therapy employing transferrin fusion proteins comprising glp-1 |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1814599A4 (en) |
| JP (1) | JP2008509153A (en) |
| KR (1) | KR20070085224A (en) |
| CN (1) | CN101035568A (en) |
| AP (1) | AP2007003920A0 (en) |
| AU (1) | AU2005271403A1 (en) |
| BR (1) | BRPI0514115A (en) |
| CA (1) | CA2575756A1 (en) |
| CR (1) | CR8954A (en) |
| EA (1) | EA200700391A1 (en) |
| GB (1) | GB2431583A (en) |
| IL (1) | IL181108A0 (en) |
| MA (1) | MA28843B1 (en) |
| MX (1) | MX2007001424A (en) |
| NO (1) | NO20071018L (en) |
| RU (1) | RU2007107808A (en) |
| TN (1) | TNSN07039A1 (en) |
| WO (1) | WO2006017688A2 (en) |
| ZA (1) | ZA200701484B (en) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
| CA2479751C (en) | 2002-03-20 | 2008-06-03 | Trent Poole | Inhalation apparatus |
| BRPI0514263B8 (en) | 2004-08-20 | 2021-05-25 | Mannkind Corp | method for the synthesis of n-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine n-protected |
| DK2314298T3 (en) | 2004-08-23 | 2015-06-15 | Mannkind Corp | Microparticles comprising diketopiperazinsalte for drug delivery |
| WO2006096515A2 (en) * | 2005-03-04 | 2006-09-14 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
| US7803404B2 (en) | 2005-09-14 | 2010-09-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
| BRPI0707991B8 (en) | 2006-02-22 | 2021-05-25 | Mannkind Corp | methods of preparing a dry powder medicine with an improved pharmaceutical property, said dry powder and using an effective amount of the dry powder |
| CA2646598C (en) | 2006-03-21 | 2014-08-19 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
| AU2007278994B2 (en) * | 2006-07-24 | 2013-08-15 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
| WO2008033395A2 (en) * | 2006-09-14 | 2008-03-20 | Biorexis Pharmaceutical Corporation | Melanocortin and transferrin fusion proteins |
| EP2195034A2 (en) | 2007-09-27 | 2010-06-16 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of making and using same |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| AU2009257311B2 (en) | 2008-06-13 | 2014-12-04 | Mannkind Corporation | A dry powder inhaler and system for drug delivery |
| US9358352B2 (en) | 2008-06-13 | 2016-06-07 | Mannkind Corporation | Dry powder drug delivery system and methods |
| DK2300083T3 (en) | 2008-06-20 | 2013-07-22 | Mannkind Corp | INTERACTIVE DEVICE AND PROCEDURE FOR REAL-TIME PROFILING INHALATION TESTS |
| TWI494123B (en) | 2008-08-11 | 2015-08-01 | Mannkind Corp | Use of ultrarapid acting insulin |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US8538707B2 (en) | 2009-03-11 | 2013-09-17 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| KR101875969B1 (en) | 2009-06-12 | 2018-07-06 | 맨카인드 코포레이션 | Diketopiperazine microparticles with defined specific surface areas |
| WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
| JP5688718B2 (en) | 2010-08-27 | 2015-03-25 | 国立大学法人 宮崎大学 | Hemokinin-1 receptor and hemokinin-1-derived peptide |
| ES2625858T3 (en) | 2011-04-01 | 2017-07-20 | Mannkind Corporation | Blister pack for pharmaceutical cartridges |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| RU2477726C1 (en) * | 2011-10-18 | 2013-03-20 | Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") | Substituted phenoxyacetic acids, their esters and amides containing 2,6-dioxo-2,3,6,7-tetrahydro-1h-pyrin-8-yl fragments - a2a adenosine receptor antagonists and use thereof |
| JP6018640B2 (en) | 2011-10-24 | 2016-11-02 | マンカインド コーポレイション | Analgesic composition effective for alleviating pain, and dry powder and dry powder drug delivery system comprising the composition |
| CN103160565A (en) * | 2011-12-09 | 2013-06-19 | 彩虹天健康科技研究(北京)有限责任公司 | Research for influence on endocytosis of cell transferrins of UNC-51 kinase |
| US9809641B2 (en) | 2012-04-23 | 2017-11-07 | Nrl Pharma, Inc. | Lactoferrin fusion protein and method for preparation thereof |
| ES2624294T3 (en) | 2012-07-12 | 2017-07-13 | Mannkind Corporation | Dry powder drug delivery systems |
| UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
| EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
| CN104902919B (en) | 2012-12-21 | 2018-11-20 | 赛诺菲 | GLP1/GIP dual agonists or the triple agonists of GLP1/GIP/ glucagon |
| EP2970149B1 (en) | 2013-03-15 | 2019-08-21 | MannKind Corporation | Microcrystalline diketopiperazine compositions and methods |
| CN103275177B (en) * | 2013-06-24 | 2015-08-12 | 南京财经大学 | There is the little peptide of feritin and ACE dual restraining activities, its preparation method and application |
| CN114848614A (en) | 2013-07-18 | 2022-08-05 | 曼金德公司 | Heat stable dry powder pharmaceutical compositions and methods |
| CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609797A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists |
| TW201609799A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Dual GLP-1/GIP receptor agonists |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
| TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
| TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
| TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| CN104645317B (en) * | 2015-01-28 | 2020-04-17 | 中国科学院天津工业生物技术研究所 | Application of polypeptide compound as polypeptide or protein drug carrier, method and fusion protein compound thereof |
| AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
| TW201706291A (en) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
| WO2018079702A1 (en) | 2016-10-28 | 2018-05-03 | 株式会社Ｎｒｌファーマ | Lactoferrin/albumin fusion protein and production method therefor |
| WO2019014552A1 (en) * | 2017-07-14 | 2019-01-17 | University Of Southern California | Insulin-transferrin fusion protein and its prodrug, proinsulin-transferrin, for overcoming insulin resistance |
| JP2021528437A (en) | 2018-06-21 | 2021-10-21 | ノヴォ ノルディスク アー／エス | New compounds for treating obesity |
| CN110218259B (en) * | 2019-06-24 | 2022-09-16 | 王跃驹 | Application of fusion protein of glucagon-like peptide-1 short peptide and transferrin produced by plants in preparing oral hypoglycemic capsules |
| CN112661862B (en) * | 2020-12-25 | 2023-03-31 | 深圳大学 | Fusion protein and preparation method and application thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| US7285526B2 (en) * | 1995-07-14 | 2007-10-23 | Meiogen Biotechnology Corporation | Interferon antagonists useful for the treatment of interferon related diseases |
| US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| ES2330082T3 (en) * | 2000-09-06 | 2009-12-04 | Aventis Pharma S.A. | METHODS AND COMPOSITIONS FOR DISEASES ASSOCIATED WITH AMYLOIDOSIS. |
| US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| WO2004019872A2 (en) * | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Oral delivery of modified transferrin fusion proteins |
| JP2005513165A (en) * | 2002-01-11 | 2005-05-12 | ノボ ノルディスク アクティーゼルスカブ | Methods and compositions for the treatment of diabetes, hypertension, chronic heart failure and fluid retention |
| WO2004020454A2 (en) * | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains |
-
2005
- 2005-08-03 ZA ZA200701484A patent/ZA200701484B/en unknown
- 2005-08-03 AP AP2007003920A patent/AP2007003920A0/en unknown
- 2005-08-03 AU AU2005271403A patent/AU2005271403A1/en not_active Abandoned
- 2005-08-03 MX MX2007001424A patent/MX2007001424A/en not_active Application Discontinuation
- 2005-08-03 BR BRPI0514115-0A patent/BRPI0514115A/en not_active IP Right Cessation
- 2005-08-03 EA EA200700391A patent/EA200700391A1/en unknown
- 2005-08-03 CN CNA2005800336740A patent/CN101035568A/en active Pending
- 2005-08-03 WO PCT/US2005/027800 patent/WO2006017688A2/en active Application Filing
- 2005-08-03 CA CA002575756A patent/CA2575756A1/en not_active Abandoned
- 2005-08-03 JP JP2007525008A patent/JP2008509153A/en not_active Withdrawn
- 2005-08-03 KR KR1020077005257A patent/KR20070085224A/en not_active Application Discontinuation
- 2005-08-03 EP EP05782173A patent/EP1814599A4/en not_active Withdrawn
- 2005-08-03 RU RU2007107808/14A patent/RU2007107808A/en not_active Application Discontinuation
-
2007
- 2007-02-01 IL IL181108A patent/IL181108A0/en unknown
- 2007-02-02 TN TNP2007000039A patent/TNSN07039A1/en unknown
- 2007-02-22 NO NO20071018A patent/NO20071018L/en not_active Application Discontinuation
- 2007-02-26 GB GB0703685A patent/GB2431583A/en not_active Withdrawn
- 2007-03-02 MA MA29727A patent/MA28843B1/en unknown
- 2007-03-02 CR CR8954A patent/CR8954A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TNSN07039A1 (en) | 2008-06-02 |
| GB2431583A (en) | 2007-05-02 |
| AP2007003920A0 (en) | 2007-02-28 |
| WO2006017688A2 (en) | 2006-02-16 |
| EA200700391A1 (en) | 2007-10-26 |
| ZA200701484B (en) | 2008-07-30 |
| NO20071018L (en) | 2007-04-11 |
| WO2006017688A3 (en) | 2006-08-03 |
| MA28843B1 (en) | 2007-09-03 |
| RU2007107808A (en) | 2008-09-10 |
| KR20070085224A (en) | 2007-08-27 |
| CR8954A (en) | 2007-10-02 |
| EP1814599A2 (en) | 2007-08-08 |
| GB0703685D0 (en) | 2007-04-04 |
| CN101035568A (en) | 2007-09-12 |
| CA2575756A1 (en) | 2006-02-16 |
| EP1814599A4 (en) | 2008-12-17 |
| JP2008509153A (en) | 2008-03-27 |
| IL181108A0 (en) | 2007-07-04 |
| MX2007001424A (en) | 2008-03-13 |
| AU2005271403A1 (en) | 2006-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0514115A (en) | combination therapy employing transferrin fusion proteins comprising glp-1 | |
| GEP20105111B (en) | Rage fusion proteins and methods of use | |
| DK1692158T3 (en) | VEGF binding and supported peptides for the treatment of skin diseases | |
| WO2007047829A3 (en) | Novel heterodimeric proteins and uses thereof | |
| ATE531382T1 (en) | TREATMENT METHODS OF INFLAMMATORY DISEASES WITH ACTIVE INGREDIENTS SPECIFICALLY BINDING TO HUMAN ANGIOPOIETIN-2 | |
| WO2004078777A3 (en) | Dipeptidyl-peptidase protected proteins | |
| ATE542920T1 (en) | MODIFIED HUMAN GROWTH HORMONE | |
| IL187188A0 (en) | Improved human interferon molecules and their uses | |
| EA200700210A1 (en) | Fc OPTIONS | |
| ATE415413T1 (en) | IAP BINDING COMPOUNDS | |
| DE602004011770D1 (en) | FUSION PROTEIN | |
| UA107330C2 (en) | Tuberculous protein rv3616c and its application | |
| IL189452A0 (en) | Therapy with cd4 binding peptides and radiation | |
| UY30925A1 (en) | IMMUNOGLOBULIN FUSION PROTEINS AND ELABORATION METHODS | |
| NZ562436A (en) | Toll-like receptor 14 (TLR14) and use thereof | |
| WO2006082304A3 (en) | Novel peptides which interact with anti-apoptotic members of the family of bcl-2 proteins and use thereof | |
| WO2008060634A3 (en) | Human complement c3 derivatives with cobra venom factor-like function | |
| WO2005059131A3 (en) | Protein binding miniature proteins and uses thereof | |
| ATE458819T1 (en) | CONJUGATE WITH P21 PROTEIN FOR CANCER TREATMENT | |
| ATE368687T1 (en) | THROMBOPOIETIN PROTEINS WITH IMPROVED PROPERTIES | |
| WO2006138610A3 (en) | Interferon-alpha/beta binding fusion proteins and therapeutic uses thereof | |
| ATE485831T1 (en) | TREATMENT OF NEURODEGENERATION | |
| TW200604207A (en) | A superantigen fusion protein and the use thereof | |
| DE602007012053D1 (en) | AFFINITY POLYPEPTIDE FOR THE CLEANING OF RECOMBINANT PROTEINS | |
| ES2426194T3 (en) | Enhanced toxin receptor chimeric proteins and toxin receptor chimeric proteins for the treatment and prevention of anthrax |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: BIOREXIS PHARMACEUTICAL CORPORATION (US) Free format text: TRANSFERIDO DE: BIOREXIS TECHNOLOGY, INC. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |